Dr. Nazareno Paolocci graduated in Medicine & Surgery at the University of Perugia (Italy) in 1987. In 1994, he got his PhD in Neurobiology at the same Institution. He joined Johns Hopkins Cardiology at the end 1997, becoming an Assistant Professor in Medicine in 2002. Dr. Paolocci’s research interest chiefly focuses on the modulatory role exerted by ROS and RNS on myocardial function, under normal and diseased conditions. His laboratory has pioneered studies aiming to evaluate the effects produced by nitroxyl (HNO) donors in the cardiovascular system, and the evaluation of monoamine oxidase (MAO) enzymatic activity has a major determining factor for the development of experimental congestive heart failure. More recently, Dr. Paolocci’s group started to investigate how mitochondrial alterations such as increased ROS emission affect myocardial function in the metabolic syndrome. His lab has been continuously funded by AHA (from year 2001) and from NIH (from 2004). He is a scientific founder of Cardioxyl Pharmaceuticals for the development of new HNO donors to treat acutely decompensated heart failure patients. He is in the editorial board of Journal of Pharmacology and Experimental Therapeutics, Cardiovascular Therapeutics and The American Journal of Physiology (Heart and Circulatory Physiology).